JP2012525385A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525385A5
JP2012525385A5 JP2012508485A JP2012508485A JP2012525385A5 JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5 JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5
Authority
JP
Japan
Prior art keywords
subject
disease
pharmaceutical formulation
administered
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012508485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/001282 external-priority patent/WO2010126605A1/en
Publication of JP2012525385A publication Critical patent/JP2012525385A/ja
Publication of JP2012525385A5 publication Critical patent/JP2012525385A5/ja
Withdrawn legal-status Critical Current

Links

JP2012508485A 2009-04-29 2010-04-29 神経変性および神経炎症の治療 Withdrawn JP2012525385A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17379709P 2009-04-29 2009-04-29
US61/173,797 2009-04-29
US17527009P 2009-05-04 2009-05-04
US61/175,270 2009-05-04
PCT/US2010/001282 WO2010126605A1 (en) 2009-04-29 2010-04-29 Treatment of neurodegeneration and neuroinflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014239565A Division JP2015044855A (ja) 2009-04-29 2014-11-27 神経変性および神経炎症の治療

Publications (2)

Publication Number Publication Date
JP2012525385A JP2012525385A (ja) 2012-10-22
JP2012525385A5 true JP2012525385A5 (cg-RX-API-DMAC7.html) 2013-10-10

Family

ID=43032484

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012508485A Withdrawn JP2012525385A (ja) 2009-04-29 2010-04-29 神経変性および神経炎症の治療
JP2014239565A Pending JP2015044855A (ja) 2009-04-29 2014-11-27 神経変性および神経炎症の治療
JP2016090250A Pending JP2016175926A (ja) 2009-04-29 2016-04-28 神経変性および神経炎症の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014239565A Pending JP2015044855A (ja) 2009-04-29 2014-11-27 神経変性および神経炎症の治療
JP2016090250A Pending JP2016175926A (ja) 2009-04-29 2016-04-28 神経変性および神経炎症の治療

Country Status (9)

Country Link
US (3) US20120165404A1 (cg-RX-API-DMAC7.html)
EP (3) EP3318249A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012525385A (cg-RX-API-DMAC7.html)
CN (2) CN102427727A (cg-RX-API-DMAC7.html)
AU (1) AU2010242064A1 (cg-RX-API-DMAC7.html)
CA (1) CA2760133A1 (cg-RX-API-DMAC7.html)
HK (1) HK1255133A1 (cg-RX-API-DMAC7.html)
NZ (2) NZ595941A (cg-RX-API-DMAC7.html)
WO (1) WO2010126605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
EP2653873B8 (en) 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
JPWO2010098429A1 (ja) 2009-02-27 2012-09-06 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
US20140142095A1 (en) * 2011-04-28 2014-05-22 Serket Pharma, Llc Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MX2013013781A (es) * 2011-05-26 2014-01-08 Biogen Idec Inc Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina.
PE20141639A1 (es) 2011-06-08 2014-11-08 Biogen Idec Inc Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
EP2791181A4 (en) * 2011-12-16 2015-08-05 Biogen Ma Inc SILICONE-CONTAINING FUMIC ACID ESTERS
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2862885C (en) * 2012-02-07 2020-06-02 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
JP2013220090A (ja) * 2012-04-19 2013-10-28 Tohoku Univ 眼疾患治療に使用する薬剤スクリーニング方法
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
AR094277A1 (es) * 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
CN103173544B (zh) * 2013-03-05 2015-01-28 浙江大学 Leber病之线粒体T3866C检测试剂盒及应用
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US10179118B2 (en) * 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート,インコーポレイティド (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
MY179355A (en) * 2013-12-12 2020-11-05 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
IL252962B (en) 2015-02-08 2022-07-01 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
WO2017056107A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
GR1009149B (el) * 2016-10-25 2017-10-31 Φαρματεν Αβεε Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
CN110636838A (zh) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
US11382889B2 (en) * 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration
CN108904779B (zh) * 2018-09-29 2019-12-03 南华大学 曲普瑞林的新应用
CN109364058A (zh) * 2018-12-05 2019-02-22 中南大学湘雅医院 富马酸酯及其可药用盐在制备治疗铁死亡相关疾病的药物中的应用
PH12021552668A1 (en) 2019-05-31 2022-09-19 Curacle Co Ltd Enteric tablet containing dimethyl fumarate
WO2021092536A1 (en) * 2019-11-08 2021-05-14 The Children's Hospital Of Philadelphia Compositions and methods for treating macrophage activation syndrome
CN113117081B (zh) * 2019-12-30 2024-12-24 上海海洋大学 ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2022203432A1 (ko) 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
CN115487297A (zh) * 2021-06-17 2022-12-20 清华大学 治疗神经元蜡样质脂褐质沉积症的方法和药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
JP2004041208A (ja) * 2002-07-15 2004-02-12 Sankyo Co Ltd インスリン抵抗性改善効果の評価方法
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007006308A1 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20070224638A1 (en) * 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US20080089861A1 (en) * 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2066335A4 (en) * 2006-09-26 2010-01-20 Univ Case Western Reserve ZYTOKINSIGNALISIERUNG
EP2653873B8 (en) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
EP2564839B1 (en) * 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
US20190195860A1 (en) Treatment of Neurodegeneration and Neuroinflammation
JP6941109B2 (ja) Fxrアゴニストを使用するための方法
ES2797493T3 (es) Formulaciones farmacéuticas de liberación controlada de nitazoxanida
JP6038653B2 (ja) 低頻度酢酸グラチラマー治療
US20140163100A1 (en) Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
CN110693867A (zh) 用于治疗代谢性病症的组合物和方法
CZ299960B6 (cs) Použití derivátu kyseliny fumarové
EA014189B1 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
CA2968980A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
CN110167595A (zh) 非酒精性脂肪性肝病的预防及治疗药
TWI226238B (en) Use of statins to inhibit formation of osteoclasts
BRPI0418973A (pt) composições de risedronato e seus métodos de uso
US20200069716A1 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP2007523162A5 (cg-RX-API-DMAC7.html)
JP2003252795A (ja) 軽度認知障害治療剤
MA27157A1 (fr) Methode de traitement d'affections osseuses.
CA3146794A1 (en) Use of a benzoate containing composition to treat neurodegenerative disorders
RU2000109303A (ru) Производные пиперидинилметилоксазолидинона
JPH07323043A (ja) 爪の保護剤及び爪の保護剤キット
Navarro et al. P1-418 SUSTAINED DELIVERY OF SURFACE MODIFIED DONEPEZIL HCL LOADED PCL NANOPARTICLES FOR ALZHEIMER’S DISEASE
JP2024541770A5 (cg-RX-API-DMAC7.html)
CA3213743A1 (en) Methods of treating neurodegenerative disorders with intranasal nf-kappab essential modifier (nemo)-binding domain (nbd) peptide
JP2005507884A5 (cg-RX-API-DMAC7.html)
HK40021394A (en) Compositions and methods for treating metabolic disorders